This is a demo store. No orders will be fulfilled.
Tag KRAS
Articles by tag "KRAS"
- KRAS Inhibitors — The "Undruggable Target"? A Thing of the Past KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is a key member of the RAS family. Mutations in KRAS are among the most common oncogenic drivers in several malignancies, including non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. It is estimated that KRAS mutations ...
- 2025 KRAS Targeted Drug Progress In the field of cancer research, the KRAS gene has always occupied an important and unique position. For many years, due to its complex structure and functional characteristics, KRAS has been regarded as an "undruggable" target.
- Traditional Chinese Medicine Molecule RA-V: A Potential Synergistic Factor in KRAS G12C Inhibition The KRAS G12C mutation is one of the common driver mutations in malignant tumors such as colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Recently approved KRAS G12C inhibitors like Adagrasib (MRTX849) and Sotorasib have provided unprecedented therapeutic options for patients.
- GDC-1971: SHP2 Inhibitor Ushering in a New Era of Cancer Treatment In recent years, protein tyrosine phosphatase SHP2 has become a highly regarded research target in the field of oncology in mediating the RAS-driven MAPK signaling pathway. Its treatment methods are not limited to single drug use, but also can work together with KRAS inhibitors, showing good ...